PMID- 37792175
OWN - NLM
STAT- Publisher
LR  - 20231004
IS  - 1559-0291 (Electronic)
IS  - 0273-2289 (Linking)
DP  - 2023 Oct 4
TI  - Integrative Analysis Reveals STC2 as a Prognostic Biomarker of Laryngeal Squamous 
      Cell Carcinoma.
LID - 10.1007/s12010-023-04727-z [doi]
AB  - Stanniocalcin 2 (STC2) is involved in many tumour types, but it remains unclear 
      what its biological function is in laryngeal squamous cell carcinoma (LSCC). 
      Therefore, we investigated STC2's expression, potential function, and prognostic 
      significance of in LSCC. The expression and prognosis of STC2 in LSCC were 
      described using the Gene Expression Omnibus (GEO) and The Cancer Genome Atlas 
      (TCGA) databases. In the TCGA database, the relationship between STC2 and immune 
      infiltration, expression of immune cell chemokine and receptor genes, immune cell 
      molecular marker genes, and epithelial‒mesenchymal transition (EMT) marker genes 
      were analysed. The biological processes involved in STC2 and its 
      expression-related genes were analysed comprehensively using bioinformatics. The 
      single-gene ceRNA network of STC2 was constructed in the TCGA database. Finally, 
      LSCC patients' tumour tissue STC2 expression was verified. STC2 silencing with 
      the RNAi technique was used for the determination of cellular functions in a 
      laryngeal cancer cell line. STC2 expression was higher in most tumours, including 
      LSCC, than in normal tissues and was associated with poor prognosis. The relative 
      proportions of naive B, plasma, follicular helper T, and macrophage M0 cells in 
      LSCC and normal samples differed significantly. STC2 expression correlated 
      significantly positively with that of TGFB1 (biomarker of Tregs) and 
      significantly negatively with that of D79A and CD19 (biomarkers of B cells). 
      Furthermore, STC2 affected chemokine and receptor gene expression in immune 
      cells. STC2 expression correlated with EMT marker gene expression in LSCC. STC2 
      was enriched in the PI3K/AKT signalling pathway, extracellular matrix (ECM) 
      organisation, ECM-receptor interaction, and other tumour-related signalling 
      pathways. STC2 was highly expressed in our clinical samples. N-cadherin and 
      vimentin expression were decreased in the TU686 cell line after successful 
      silencing of STC2, indicating that high STC2 expression may prompt LSCC cells to 
      adopt a mesenchymal cell phenotype. STC2 silencing substantially reduced 
      proliferation and migration in the TU686 cell line. STC2 may be a promising 
      predictive biomarker for tumours, providing new approaches for LSCC diagnosis and 
      treatment monitoring.
CI  - (c) 2023. The Author(s), under exclusive licence to Springer Science+Business 
      Media, LLC, part of Springer Nature.
FAU - Zhong, Rong
AU  - Zhong R
AD  - School of Medicine, South China University of Technology, Guangzhou, China.
FAU - Zhan, Jiandong
AU  - Zhan J
AD  - Department of Otorhinolaryngology, Guangdong Provincial People's Hospital, 
      Guangdong Academy of Medical Sciences, Guangzhou, China.
FAU - Zhang, Siyi
AU  - Zhang S
AUID- ORCID: 0000-0001-8669-5285
AD  - School of Medicine, South China University of Technology, Guangzhou, China. 
      zhangsiyi@gdph.org.cn.
AD  - Department of Otorhinolaryngology, Guangdong Provincial People's Hospital, 
      Guangdong Academy of Medical Sciences, Guangzhou, China. zhangsiyi@gdph.org.cn.
LA  - eng
GR  - 202002020024/Guangzhou Municipal Science and Technology Project/
PT  - Journal Article
DEP - 20231004
PL  - United States
TA  - Appl Biochem Biotechnol
JT  - Applied biochemistry and biotechnology
JID - 8208561
SB  - IM
OTO - NOTNLM
OT  - Bioinformatics
OT  - Laryngeal squamous cell carcinoma
OT  - Patient-derived organoids
OT  - Prognostic biomarker
OT  - STC2
OT  - The Cancer Genome Atlas (TCGA) databases
EDAT- 2023/10/04 12:45
MHDA- 2023/10/04 12:45
CRDT- 2023/10/04 11:11
PHST- 2023/09/15 00:00 [accepted]
PHST- 2023/10/04 12:45 [medline]
PHST- 2023/10/04 12:45 [pubmed]
PHST- 2023/10/04 11:11 [entrez]
AID - 10.1007/s12010-023-04727-z [pii]
AID - 10.1007/s12010-023-04727-z [doi]
PST - aheadofprint
SO  - Appl Biochem Biotechnol. 2023 Oct 4. doi: 10.1007/s12010-023-04727-z.